10-Q: DiaMedica Therapeutics Reports Q1 2024 Financial Results and Provides Update on Clinical Trial

DiaMedica Therapeutics reported a net loss of $5.2 million for the first quarter of 2024, while continuing to advance its ReMEDy2 clinical trial for acute ischemic stroke.

Summary

• DiaMedica Therapeutics reported a net loss of $5.2 million for the three months ended March 31, 2024, compared to a net loss of $5.3 million for the same period in 2023.
• The company's research and development expenses were $3.7 million for the quarter, slightly up from $3.6 million in the prior year.
• General and administrative expenses increased to $2.1 million from $1.9 million year-over-year.
• Other income, primarily from interest on marketable securities, increased to $597,000 from $256,000 in the prior year.
• As of March 31, 2024, DiaMedica had $46.5 million in cash, cash equivalents, and marketable securities.
• The company's working capital was $44.9 million, and total shareholders' equity was $46.3 million.
• The ReMEDy2 clinical trial for acute ischemic stroke is ongoing, with plans to expand globally to Canada, Australia, the United Kingdom, and Europe.
• The company expects current cash resources to be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has sufficient cash for the next 12 months and is expanding its clinical trial, it is still incurring losses, experiencing delays, and may need to raise additional capital. The sentiment is neutral to slightly negative due to the ongoing challenges.

Positives

• The net loss slightly improved compared to the same quarter last year.
• The company has a substantial amount of cash and marketable securities on hand.
• Interest income increased due to higher marketable securities balances.
• The ReMEDy2 trial is expanding globally, which may accelerate enrollment.
• Current cash resources are expected to fund operations for at least the next 12 months.

Negatives

• The company continues to incur significant operating losses.
• Site activations and enrollment in the ReMEDy2 trial have been slower than expected.
• The company is still in the clinical stage and does not generate revenue from product sales.
• The company is dependent on additional financing to continue operations.

Risks

• The company's future success depends on the success of its clinical trials and regulatory approvals.
• There are risks associated with the ReMEDy2 trial, including slower site activations and enrollment, and potential adverse events.
• The company faces competition for research staff and trial subjects.
• The company may need to raise additional capital, which could dilute existing shareholders.
• There is no guarantee that the company will be able to obtain regulatory approval for its product candidate.

Future Outlook

The company expects to continue the ReMEDy2 trial and fund operations for at least the next 12 months, while also planning to disclose its cardio-renal program plans in the second half of 2024. They anticipate that quarterly expenses will increase as the ReMEDy2 trial expands globally and enrollment increases.

Management Comments

• Management believes that the slower site activations and enrollment in the ReMEDy2 trial are due to hospital staffing shortages, concerns regarding prior hypotension events, protocol compliance issues, revised inclusion/exclusion criteria, and competition for research staff and trial subjects.
• Management intends to continue to monitor the results of efforts to mitigate the impact of these factors and, if necessary, implement additional actions.

Industry Context

DiaMedica is operating in the competitive biopharmaceutical industry, specifically targeting treatments for acute ischemic stroke and cardio-renal diseases. The company's focus on recombinant KLK1 protein is a novel approach, but it faces competition from established treatments and other companies developing therapies for similar indications. The global expansion of the ReMEDy2 trial reflects a broader trend in clinical research to access diverse patient populations and accelerate trial timelines.

Comparison to Industry Standards

• DiaMedica's cash burn rate of approximately $6.7 million in operating activities for the quarter is typical for a clinical-stage biotech company, but it is important to compare this to companies with similar pipelines and trial stages.
• Companies like Actelion (acquired by J&J) and Genentech (a Roche subsidiary) have developed stroke treatments, but they are larger and more established. DiaMedica's approach with DM199 is different, targeting a specific patient population not addressed by existing treatments.
• The company's R&D spending of $3.7 million is in line with other companies at a similar stage of development, but the efficiency of this spending will be determined by the success of the ReMEDy2 trial.
• The global expansion of the ReMEDy2 trial is a common strategy to accelerate enrollment, but it also increases costs and logistical complexity. Companies like Biohaven and Argenx have successfully conducted global trials, providing a benchmark for DiaMedica.

Legal Proceedings

• DiaMedica is involved in ongoing litigation with ICON/PRA Netherlands regarding ownership of clinical study data.
• The company has appealed a decision related to damages in the ICON/PRA Netherlands case.
• The company may be subject to other legal actions in the ordinary course of business.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost reduction strategies if funding is not secured.
• Patients with acute ischemic stroke may benefit from the development of DM199 if the clinical trials are successful.
• The company's suppliers and vendors may be impacted by changes in the company's financial situation.

Next Steps

• Continue the ReMEDy2 clinical trial for acute ischemic stroke.
• Expand the ReMEDy2 trial globally to include sites in Canada, Australia, the United Kingdom, and Europe.
• Monitor and address the slower than expected site activations and enrollment in the ReMEDy2 trial.
• Disclose plans for the cardio-renal program in the second half of 2024.
• Potentially seek additional funding to support operations and clinical trials.

Key Dates

Keywords

DM199, clinical trial, acute ischemic stroke, cardio-renal disease, ReMEDy2, biopharmaceutical, research and development, financial results, regulatory approval, kallikrein-1